肥胖合并肝硬化患者减重手术的生存获益与成本效益
该回顾性队列研究纳入美国退伍军人中BMI>35或BMI>30且合并代谢病的肥胖患者,比较减重手术(袖状胃切除或Roux-en-Y胃旁路)与结构化生活方式干预(MOVE!)的10年成本效益与生存。减重手术与更长生存相关,在肝硬化患者中增量成本效益比低于10万美元/质量调整生命年阈值,具有成本效益。
要点
- 减重手术与肥胖患者更长生存相关,肝硬化亚组亦获益。
核心结论
- 减重手术与改善生存和预期体重下降相关,并具有成本效益。
- 研究结果支持在适当选择的肥胖患者中扩大减重手术应用,包括肝硬化患者。
研究设计与样本
- 经济评估为回顾性队列研究,纳入2008至2020年美国退伍军人中BMI>35或BMI>30且合并>1种主要代谢合并症并转诊至MOVE!项目者。
主要发现
- 与MOVE!相比,减重手术与更长观察生存相关:总体9.67年 vs 9.46年,肝硬化患者9.09年 vs 8.23年。
关键数值与推荐
- 在肝硬化患者中,减重手术在每质量调整生命年10万美元的支付意愿阈值下具有成本效益。
临床怎么用
- 对适当选择的肥胖患者(包括肝硬化患者),可考虑减重手术以改善生存并降低长期医疗成本。
局限性
- 本研究为回顾性队列设计,肝硬化亚组样本量小(袖状胃切除64例、Roux-en-Y胃旁路8例、MOVE! 354例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Obesity and steatotic liver disease are associated with excess morbidity and mortality from cardiovascular, pulmonary, metabolic, and hepatic causes. Bariatric surgery has demonstrated long-term benefits in terms of weight loss and mortality rates, but barriers to its utilization persist. OBJECTIVE: To evaluate the impact of bariatric surgery on outcomes and cost-effectiveness among patients with obesity, focusing on those with cirrhosis. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation was a retrospective cohort study including US veterans older than 18 years with a body mass index (BMI) higher than 35 or with a BMI higher than 30 and more than 1 major metabolic comorbidity. These veterans were referred to a structured lifestyle modification program (MOVE!), and a subset proceeded to bariatric surgery, including sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) from 2008 to 2020. Risk set matching was used to match bariatric surgery cases 1:5 with nonsurgical controls. Data were analyzed from September 2008 to September 2023. EXPOSURES: Bariatric surgery (SG or RYGB) or structured lifestyle intervention (MOVE!). MAIN OUTCOMES AND MEASURES: The primary outcomes were the incremental cost-effectiveness ratio (ICER) of SG or RYGB vs MOVE! over 10 years. Secondary outcomes included overall survival, quality-adjusted survival, and weight loss achieved. RESULTS: The final cohort included 4301 SG, 1906 RYGB, and 31 055 MOVE! participants, among whom 64, 8, and 354, respectively, had cirrhosis. The median (IQR) age of the cohort was 52 (44-59) years; there were 25 581 male patients (68.7%) and 11 681 female (31.3%). Compared with MOVE!, bariatric surgery was associated with longer observed survival (9.67 years vs 9.46 years overall; 9.09 years vs 8.23 years in cirrhosis). The ICER was $132 207 for SG and $159 027 for RYGB in the overall cohort, and $18 679 for SG and $44 704 for RYGB in the cirrhosis cohorts. Bariatric surgery was cost-effective at a willingness-to-pay threshold of $100 000 per quality-adjusted life-year among patients with cirrhosis. CONCLUSIONS AND RELEVANCE: Bariatric surgery was associated with improved survival and expected weight loss and was cost-effective. These findings support the expanded use of bariatric surgery in appropriately selected patients, including those with cirrhosis, to improve outcomes and reduce long-term health care costs.
引用
- Bansal S, Bader A, Mahmud N, et al. Survival and Cost-Effectiveness of Bariatric Surgery Among Patients With Obesity and Cirrhosis. JAMA Surg. 2025. PMID: 40172871. doi:10.1001/jamasurg.2025.0490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。